Mohammed Shahait: Our new study “Termination of Urologic Cancer Trials”

Mohammed Shahait, Clinical Instructor of Urology at The University of Pennsylvania and The University of Pittsburgh Medical Center, shared on X/Twitter:

“Our new study “Termination of Urologic Cancer Trials” at JCO Global Oncology.

25% termination rate.

Main cause: Low patient accrual.
Risk factors: University funding, single-center, small sample.”

Additional information.

Source: Mohammed Shahait/X